Last updated on October 2005

Efficacy of G-CSF-Priming in Elderly AML Patients


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Acute Myeloid Leukemia
  • Age: Between 61 - 100 Years
  • Gender: Male or Female
  • Other:
    Diagnosis of de-novo AML, FAB M0, 1, 2, 4-7 or
    Diagnosis of secondary AML after previous chemotherapy and/or radiation therapy or
    after preceeding MDS or
    Diagnosis of an advanced MDS, i.e. RAEB-t according to the FAB classification or
    Extramedullary AML (chloroma, “granulocytic sarcoma”)
    Age greater than 60 years (not including 60 years)
    ECOG performance status 0, 1, or 2
    Written informed consent

You may not be eligible for this study if the following are true:

  • Patients with a t(15;17) translocation
    Patients with severe cardiac disease (e.g. cardiac failure NYHA III/IV, myocardial
    infarction within the last 6 months; severe ventricular arrythmias (Lown III or IV)
    Patients with severe complications of the leukemia such as uncontrolled bleeding,
    pneumonia with hypoxia or shock.
    Severe pulmonary disease (diffusion capacity for CO2 of less than 50%)
    Significant renal dysfunction (creatinine clearance < 60/min/min)
    Bilirubin > 2mg% (>34.2 mmol/l)
    Patients with a clinically active second malignancy
    Patients with a psychiatric, addictive, or any disorder wich compromises ability to
    give truly informed consent for participating in this study
    HIV positivity
    Known refractoriness to platelet transfusion, inability to adequately substitute
    blood products

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.